Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a biotechnology company focused on precision genetic medicine for rare diseases, with a stated leadership position in Duchenne muscular dystrophy and an expanding portfolio across muscle, central nervous system and cardiac conditions. The SRPT news feed on Stock Titan aggregates company-issued updates and market-moving announcements that reflect Sarepta’s scientific, regulatory and financial developments.
Investors and followers of SRPT can use this page to review earnings and revenue updates, such as preliminary net product revenue reports that break out contributions from ELEVIDYS and the company’s PMO franchise, as well as quarterly financial results and commentary on cash position and capital structure. News items also cover clinical and regulatory milestones, including updates to the ELEVIDYS prescribing information, FDA safety labeling decisions, and the design and progress of studies like ENDEAVOR and ESSENCE.
The feed highlights pipeline progress in Sarepta’s next-generation siRNA platform, including clinical trial applications and early-stage data for programs such as SRP-1003 for myotonic dystrophy type 1 and SRP-1005 for Huntington’s disease. It also captures disclosures about strategic restructuring, clinical holds in limb girdle muscular dystrophy gene therapy programs, and collaborations with partners like Arrowhead Pharmaceuticals.
Corporate and capital markets news—such as convertible note exchanges, private placements of common stock, inducement grants under Nasdaq Listing Rule 5635(c)(4), and investor conference presentations—are also included. By reviewing this consolidated SRPT news stream, users can quickly see how Sarepta communicates its progress in genetic medicine, regulatory interactions, financing activities and strategic priorities over time.
Sarepta Therapeutics (NASDAQ:SRPT) granted inducement equity awards on March 31, 2026 to 24 employees hired in Q1 2026 under the company’s 2024 Employment Commencement Incentive Plan. The awards total 113,855 restricted stock units (RSUs) and vest 25% annually over four years, subject to continued employment. Awards were approved pursuant to Nasdaq Listing Rule 5635(c)(4). No stock options were granted.
Sarepta (NASDAQ:SRPT) reported first clinical data from Phase 1/2 studies of two αvβ6 integrin-targeted siRNA candidates, SRP-1001 (FSHD1) and SRP-1003 (DM1).
Early results show dose-dependent muscle and plasma exposures, single-dose target knockdown, and favorable tolerability with no dose-limiting toxicities reported to date. An investor webcast is scheduled March 25, 2026.
Sarepta (NASDAQ:SRPT) will present early clinical results from Phase 1/2 ascending‑dose studies of SRP‑1001 (FSHD1) and SRP‑1003 (DM1) on March 25, 2026 at 8:30 AM ET via live webcast and conference call.
Replay will be archived on the investor relations site for one year; phone participants must register to receive dial‑in and PIN details.
Sarepta (NASDAQ:SRPT) will submit supplemental NDAs by the end of April 2026 seeking conversion of AMONDYS 45 and VYONDYS 53 accelerated approvals to traditional approvals.
ESSENCE topline showed non‑significant primary results (LSM difference 0.06 steps/sec, P=0.309); an updated COVID‑adjusted analysis reached P=0.050. No new safety signals; company will include ESSENCE and real‑world evidence in the sNDAs.
Sarepta (NASDAQ:SRPT) announced screening and enrollment are underway in ENDEAVOR Cohort 8 to test a prophylactic sirolimus-enhanced immunosuppression regimen alongside ELEVIDYS in non-ambulatory Duchenne patients. Approximately 25 participants will receive 14 days of peri-infusion sirolimus plus continued dosing for 12 weeks. Primary endpoints are incidence of acute liver injury (ALI) and ELEVIDYS-dystrophin expression at 12 weeks. ENDEAVOR has enrolled 55 participants across seven cohorts; ELEVIDYS has been administered to over 1,200 patients globally. The cohort aims to assess whether sirolimus mitigates ALI risk in older, non-ambulatory patients.
Sarepta Therapeutics (NASDAQ:SRPT) opened applications for Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year. Scholarships of up to $5,000 will be awarded to up to 20 individuals with Duchenne and up to 5 siblings.
Applications are accepted through May 15, 2026; recipients will be notified before July 31, 2026 and awards distributed to schools for fall 2026 enrollment.
Sarepta Therapeutics (NASDAQ:SRPT) will present new long-term efficacy, safety and caregiver-reported data at the Muscular Dystrophy Association Clinical & Scientific Conference, March 8–11, 2026 in Orlando.
Key items include a late-breaking oral on delandistrogene moxeparvovec (EMBARK) functional outcomes up to 3 years versus a matched external control, a pooled safety analysis with up to 7.5 years follow-up, Phase 3 ESSENCE topline results for golodirsen and casimersen, caregiver impressions through 2 years, and multiple real-world and pharmacokinetic posters.
Sarepta Therapeutics (NASDAQ:SRPT) reported Q4 2025 and full‑year results on Feb 25, 2026: FY2025 revenue $2,198.2M (+16% YoY), Q4 revenue $442.9M, and net product revenue for FY2025 of $1,864.3M (PMO $965.6M; ELEVIDYS $898.7M). GAAP net loss for FY2025 was $713.4M (GAAP diluted loss per share $7.13). Cash, cash equivalents and investments were $953.8M at 12/31/2025. Corporate actions included refinancing 2027 notes into 2030 notes, ELEVIDYS launch in Japan (eligible $40M milestone), positive 3‑year EMBARK data, and advancing multiple siRNA programs with a Huntington’s CTA approved to start in Q2 2026.
Sarepta Therapeutics (NASDAQ:SRPT) announced the commercial launch of ELEVIDYS in Japan on February 24, 2026, via Chugai after National Health Insurance reimbursement and MHLW conditional, time-limited approval (May 2025).
ELEVIDYS is available for ambulatory Duchenne patients aged 3 to less than 8 years with deletions in exon 8 and/or exon 9 and negative anti-AAVrh74 status; the first Japan sale triggers a $40 million milestone payment to Sarepta.
Sarepta Therapeutics (NASDAQ:SRPT) said senior management will appear in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026 at 1:50 p.m. ET. The presentation will be webcast live via the company's investor relations site and archived for 90 days.
Investors are advised to connect several minutes early to allow time for any required software downloads.